Therefore, our results show that combinatorial inhibition of ERRα and mTORC1/S6K1 may have clinical utility in treatment of triple-negative breast cancer, and warrants further investigation. This evidence concerns the gene RPS6KB1 and triple-negative breast carcinoma.